title: [Pandoraea sputorum colonization in a patient with cystic fibrosis].
abstract: Cystic fibrosis (CF) is a disease produced by a defect in the transmembrane conductance regulator protein, CFTR. Currently, the morbidity and mortality associated with CF are fundamentally related with the lung affectation that is a consequence of this defect. With the progression of the disease, there is an increase in the isolation of non-fermenting gram-negative bacilli colonizing these patients. The genus Pandoraea arises from a reclassification of species included within the "Burkholderia cepacia complex". It is made up of 9 species susceptible only to tetracycline, imipenem and cotrimoxazole. We report the first clinical case in Spain of colonization by Pandoraea sputorum in a patient diagnosed with CF at the age of eleven. After several previous colonizations by different Pseudomonas species in September 2005, a gram-negative bacillus was isolated in sputum, which was identified by sequencing and mass spectrometry (MALDITOF-MS) as P. sputorum, only sensitive to piperacillin-tazobactam, cotrimoxazole and imipenem. From 2005 to 2008, chronic colonization by this microorganism was associated with deterioration in lung function that was recuperated after treatment with piperacillin-tazobactam and imipenem. In 2010, this microorganism was once again isolated and treated with imipenem, to which the patient responded favorably. Currently, it is not known whether this microorganism is a chronic colonizer, whether it produces a transitory infection or whether it constitutes an important problem in CF patients, but given its special characteristics of sensitivity to anti-microbial drugs, the correct identification of this genus is essential. Mass spectrometry seems to be a valid technique that is faster than sequencing methods for identifying these species.
authors: Servicio de Microbiología y Parasitología, Complexo Hospitalario Universitario de Santiago de Compostela, La Coruña, España. lu 13128@hotmail.com
authors: Lucía
authors: L
authors: Martínez-Lamas
authors: Carlos
authors: C
authors: Rabade Castedo
authors: Miguel
authors: M
authors: Martín Romero Domínguez
authors: Gema
authors: G
authors: Barbeito Castiñeiras
authors: Ana
authors: A
authors: Palacios Bartolomé
authors: María Luisa
authors: ML
authors: Pérez Del Molino Bernal
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001987:Bronchiectasis / Q000209:etiology / Q000382:microbiology; D019121:Burkholderia Infections / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D042602:Burkholderia cepacia complex / Q000187:drug effects / Q000302:isolation & purification* / Q000472:pathogenicity; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology; D016207:Cytokines / Q000378:metabolism; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D013183:Sputum / Q000382:microbiology; D015163:Superinfection; D014774:Virulence
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines; D015378:Imipenem